← All trials
NCT01112787
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 26, 2010
- Primary completion
- Apr 26, 2010
- Completion date
- Apr 26, 2010
- First posted
- —
- Last posted
- —
- Enrollment
- 39
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Stiefel LaboratoriesLead sponsor
- GlaxoSmithKlineStudy director
- GlaxoSmithKlineCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.